Introduction:
Pharma stock has introduced India’s first Quadrivalent Inactivated Influenza vaccine, VaxiFlu-4, offering protection against four new flu strains for the 2025 Southern Hemisphere. Approved by CDL, it aligns with WHO recommendations, enhancing seasonal flu protection and strengthening India’s public health efforts.
Share Price movement of Zydus Lifesciences :
On February 27, 2025, Zydus Lifesciences Limited opened at ₹887.45, reaching a high of ₹905.00, up 2.49% from its previous close of ₹882.95 and a low of ₹872.35. Currently, the stock is trading at ₹877.40, with a market cap of ₹88,286.97 crore.
Zydus Lifesciences launched new vaccine:
Zydus Lifesciences has become the first in India to launch a Quadrivalent Inactivated Influenza vaccine, VaxiFlu-4, offering protection against four new influenza strains for the 2025 Southern Hemisphere. Approved by India’s Central Drug Laboratory (CDL), the vaccine aligns with WHO’s recommended composition for flu prevention.
Developed at Zydus’ Vaccine Technology Centre (VTC) in Ahmedabad, VaxiFlu-4 is marketed by Zydus Vaxxicare, a division focused on preventive healthcare. The vaccine provides broader coverage against both Influenza A and B strains, reducing the risk of vaccine mismatch and enhancing seasonal flu protection in India.
Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, emphasized the importance of annual flu vaccinations to prevent outbreaks and serious complications, particularly among children, the elderly, and immunocompromised individuals. With 290,000-650,000 annual flu-related deaths globally, the vaccine strengthens India’s public health efforts against influenza.
Also Read: Stock jumps after announcing 1:10 stock split and ₹14.5 dividend
Recent news About Zydus Lifesciences :
In January 2025, Zydus Lifesciences received approval from the USFDA to conduct a Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor, in patients with Amyotrophic Lateral Sclerosis (ALS).
Stock performance of Zydus Lifesciences for Period of 1 week, 6 months and 1 year:
Zydus Lifesciences’ stock declined 1.86% over the past week, reflecting short-term weakness. Over the last six months, it dropped 21.7%, indicating significant bearish sentiment. In the past year, the stock fell 5.32%, showing an overall downtrend despite the company’s efforts in pharmaceutical innovation and expansion.
Also Read: Railway stock jumps after it secures order worth ₹255 Cr from Braithwait & Co
Shareholding pattern of Zydus Lifesciences :
| All values in % | Dec-24 | Sep-24 | Jun-24 |
| Promoters | 74.98 | 74.98 | 74.98 |
| FII | 7.53 | 7.52 | 5.59 |
| DII | 10.66 | 10.64 | 12.63 |
| Retail & others | 6.85 | 6.85 | 6.81 |
About Zydus Lifesciences :
Zydus Lifesciences is a leading Indian pharmaceutical company specializing in drug discovery, generics, vaccines, and biotechnology. With a strong global presence, it focuses on innovative healthcare solutions, including influenza vaccines, contributing to public health advancements and affordable medicine access worldwide.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
